entertainment -WSS

entertainment

author：knowledge 2025-09-30 17:28:12 - browse：5

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： What affirmative action's end means to a medical student

WSS

'Screen and refer' systems are hurting patients

Readout LOUD podcast: A CRISPR milestone, biotech mixology

FDA's Woodcock to retire early next year

Drug cartel violence flares in western Mexico after vigilante leader's killing

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

U.K. considers world's first use of meningitis vaccine to address gonorrhea

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Affirmative action in medical school literally saved lives

Wegovy, Zepbound and weight loss drugs that preserve muscle

Apple is now the first public company to be valued at $3 trillion

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

PBM reforms clear House panel

Duchenne breakthrough therapy leaves behind pioneering families

How Robert F. Kennedy Jr. distorted vaccine science

Hepatitis C has a cure — but many Americans still lack access to it

Prescription digital therapeutics are key to pharma’s future

hotspot

Astellas still sees hope in its gene therapy after four deaths

Does good food count as health care? Study aims to find out

Fatty liver disease was alleviated by Lilly’s ‘triple

Crowdfunding for unproven stem cell procedures spreads misinformation

Congress must reauthorize a committee to support older Americans

STAT wants to know your pick for a great summer read or listen

explore

hotspot

explore

hotspot